A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Adagrasib in Patients with KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 204)

Protocol No
VERASTEM-VS-6766-204
Phase
I/II
Summary

This project is being done to find out the best dose/ understand the safety of VS-6766 and
adagrasib when taken together, learn how well and how long the study treatment of VS-6766 taken with adagrasib works, measure the amount of VS-6766, adagrasib and compounds related to the study drugs in the blood.

Description
A Phase 1/2 Study of VS-6766 in Combination with Adagrasib in Patients with KRAS G12C mutant NSCLC
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL